Medical/Pharmaceuticals
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study
* ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology inthe United States * The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumor...
2024-03-20 20:30
2480
Innovent Announces 2023 Annual Results and Business Updates
A transformative year of strong performance and material innovation progress ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...
2024-03-20 19:44
3996
Johnson Matthey signs agreement to sell its Medical Device Components business for US$700m
Johnson Matthey Plc This announcement contains inside information LONDON, March 20, 2024 /PRNewswire/ -- Johnson Matthey Plc (JM) announces that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consider...
2024-03-20 19:10
2434
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
LAKE FOREST, Calif., March 20, 2024 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have bee...
2024-03-20 16:22
2169
BGI Group Celebrates 20th Anniversary of Partnerships in Healthcare and Genomics in Thailand
BANGKOK, March 20, 2024 /PRNewswire/ -- This year marks the twentieth anniversary of BGI Group's close relationship with the Kingdom ofThailand. Initially both parties were brought together through an international humanitarian rescue effort during the Indian Ocean tsunami where BGI worked with ...
2024-03-20 12:39
2015
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
Proceeds to Support Advancement of Engrail's Pipeline for Neuropsychiatric and Neurodevelopmental Disorders SAN DIEGO, March 20, 2024 /PRNewswire/ -- Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to impro...
2024-03-20 11:00
1947
Docquity enables Italian biopharmaceutical company Menarini to double HCP reach and engagement in Malaysia
* A Docquity client since 2021, Menarini Malaysia further engaged the platform to raise awareness among target HCPs on multimodal approaches to post-surgery pain management and recovery * Docquity's Awareness to Advocacy (A2A) Program, backed by its in-depth HCP network insights, droveMenarini...
2024-03-20 10:00
1959
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
SHANGHAI, March 20, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Singapore Health Sciences ...
2024-03-20 09:16
2074
FDI World Dental Federation releases powerful video message unifying voices in celebration of World Oral Health Day
In celebration of World Oral Health Day, FDI World Dental Federation debuts an impactful video message uniting voices from diverse sectors, advocating for collective efforts to improve oral health worldwide. GENEVA, March 20, 2024 /PRNewswire/ -- "A Happy Mouth is a Happy Body," says FDI World D...
2024-03-20 09:00
1689
Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research
SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...
2024-03-20 08:30
1999
China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, March 19, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...
2024-03-20 04:05
2110
Datasea Enters into Manufacturing Agreement to Accelerate Production and Deployment of its Hi-Tech Intelligent Acoustic Products
BEIJING, March 19, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and C...
2024-03-19 22:00
1483
SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential
SHANGHAI, March 19, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire industry chain, presented the clinical study data of the 9MW2821 for patients with cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology ...
2024-03-19 22:00
1572
Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate
* A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis * Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to 60 sites in seven countries * The M72/AS01E vac...
2024-03-19 21:02
1586
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
ST. GALLEN, SWITZERLAND, March 19, 2024 /PRNewswire/ -- CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations ...
2024-03-19 19:09
2323
Samsung Medison and Bracco Imaging Forge Path with New Diagnostic Ultrasound Technology Agreement at ECR 2024
The collaboration aims to improve ultrasound contrast agent utilization and image resolution, streamline workflow, and enhance clinical benefits for users and patients. MILAN, March 19, 2024 /PRNewswire/ -- Samsung Medison (CEO, Mr. Yongkwan Kim) and Bracco Imaging (CEO, Dr. Fulvio Renoldi Bracc...
2024-03-19 18:00
2220
LifeSpan Vision Ventures Invests in SENISCA
NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter. The company has developed proprietary technology that har...
2024-03-19 17:00
1675
Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo
Cognizant's AI and industry expertise, combined with the NVIDIA BioNeMo generative AI platform, create a strong foundation to improve outcomes in the healthcare and life sciences sectors TEANECK, N.J., March 19, 2024 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) is advancing the application of genera...
2024-03-19 12:01
2638
Takeda Hospital Group Joins TriNetX Network to Revolutionize Medical Care in Japan
CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Takeda Hospital Group, a leading healthcare provider inKyoto, Japan Prefecture, has joined the TriNetX, LLC (TriNetX) network. Recognizing the need for tailored treatments based on the distinct genetic and lifestyle factors of Japanese patients, T...
2024-03-19 12:01
1512
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
* The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; * The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; * The China new drug application submiss...
2024-03-19 10:24
1381
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116